Latest News and Information

We'll be posting articles on this page from time to time, on a range of topics, to keep you updated and informed.  We'll notify you via Facebook when a new article is posted, so make sure you keep an eye on that and like our page .Facebook thumbs up

We are currently running a study for Hepatitis C in all three of our units, in Tauranga, Hawke's Bay and Wellington.  We've compiled some information on this disease.  Further details on the study itself can be found on our Current Studies page.

 

HEPATITIS C
 

What is Hepatitis C?

Hepatitis C is a disease caused by the Hepatitis C virus (HCV).  It causes chronic inflammation of the liver. Many people have no symptoms until the late stages of the disease, but it can cause persistent fatigue, nausea, loss of appetite or generalised aches.

There are currently eleven different types of HCV, referred to as genotypes, because there are genetic differences between them, which have evolved over time (thousands of years).  This is like the way that there are different breeds of dogs, which behave differently, but they are the same species.  Different genotypes can affect the illness course and response to drug treatments, which is why it is important to know which genotype a patient has, before beginning medication.  The genotypes are numbered 1 to 11.  Most people in New Zealand have type 1, and smaller numbers have types 2 and 3.  It is possible to be infected with more than one type at the same time.

There are many other causes of hepatitis, including other viruses like hepatitis A and E, which are transmitted by infected food or water, hepatitis B and D, which are spread sexually and through blood contact, and non-infectious causes like alcohol, some medications, and some types of auto-immune disease.

How common is it?

Many people with hepatitis C are undiagnosed, so it is difficult to know for sure.  It is estimated that 50,000 people in New Zealand are infected, but that only half of these are aware of it.  Many of these people were infected 20-30 years ago.  Rates of hepatitis C are very high in people who have been in prison.  Worldwide, about 180 million people have hepatitis C (about 3% of the population) with highest rates in central and eastern Asia, North Africa, and the Middle East.

How do you catch it?

Hepatitis C is a blood-borne disease, so is usually transmitted through contaminated needles or injecting equipment.  It can also be acquired through accidental blood contact e.g. needle-stick injury, or exposure of broken skin to infected blood e.g. during sports injuries, or from mother to child.  The virus can survive outside of the body for up to seven days.

In the past, some people were infected by blood transfusion, but New Zealand has been screening donated blood since 1992.  Infections have also occurred overseas from medical treatment, body piercing or tattoos using unsterile equipment.

Hepatitis is not transmitted through normal social contact, or through coughing/sneezing, and is rarely transmitted sexually.

How do I get tested?

Hepatitis C is diagnosed by a blood test, which can be arranged by your GP, or by contacting the Hepatitis Foundation http://www.hepatitisfoundation.org.nz.

The first-line test is for antibodies to HCV.  If this is positive, a HCV RNA/Antigen test is done, which confirms presence of the virus.  If the antibody test is positive, but the antigen test is negative, this suggests the person has had a previous infection with HCV which has either cleared spontaneously, or been treated.

Is it serious?

A minority of people (about 20%) clear the virus naturally within two to six months of infection.  This can depend on the genotype of the virus.  Most people, however, remain chronically infected, and can therefore pass on the disease to others.  If you have had the virus a long time, it is very unlikely to clear on its own.

Over time, liver damage becomes permanent, and can lead to chronic liver disease in 60-70% of cases, and cirrhosis (liver scarring) in about 30%.  Cirrhosis can in turn lead to liver cancer, but this is rare.

How is it treated?

In the past, hepatitis C was treated with a drug called interferon, which had high rates of side-effects and was only partially successful.  New anti-viral drug combinations, called directly acting anti-viral medicines (DAAs) have significantly improved the success rate of treatment, in many cases leading to a permanent cure.  These have been available in New Zealand for several years, and became funded for treatment through General Practitioners from 1 July 2016.  This involves a twelve week course of tablets.  Currently only people with type 1 HCV, who do not have cirrhosis, can be treated by their GP, other types have to be referred to a specialist for treatment.

Can it be prevented?

There is currently no vaccine against hepatitis C.  The best way to prevent it is to never use unsterile needles, and avoid contact with other peoples blood.

If you have hepatitis C, the best way to avoid infecting others is to stop them coming in contact with your blood: never share toothbrushes, razors or injecting equipment, do not donate blood, cover any cuts or scrapes, and clean up any blood spills with disinfectant as soon as possible.  Getting curative treatment for yourself will avoid you accidentally passing the virus on to your loved ones.

Current trial:

P3 Research is currently running a trial of a new combination of directly acting anti-viral medicines. The new treatment is expected to lead to a shorter treatment course, with fewer side-effects.  This study is being run in all three of our units, in Tauranga, Hawke's Bay and Wellington. 

We are looking for people with type 1 or 2 HCV, who have cirrhosis of the liver, and have never had treatment of their hepatitis C before.  Participants will take daily tablets for up to 12 weeks, and everyone will receive active treatment.  There is a screening period (up to 50 days) and a follow-up period (24 weeks), so you would be in the trial for up to 43 weeks.  You would need to have multiple blood tests throughout the trial, and parts of the study will involve spending several hours in our unit.  There is no cost to you for the tests or treatment, and participants are reimbursed for reasonable expenses related to their visits.

To find out more and see if you can take part, please contact us, and we can send you the Participant Information Sheet which explains it all in detail.  To know if you can take part, you would first need to have a special test, like an ultrasound scan, called a FibroScan.  This measures the amount of fibrosis (scarring or damage) in the liver, so gives an estimate of the presence and severity of cirrhosis.  This test is simple and painless.  If you would like to arrange this, please contact your nearest unit.

Tauranga: 07 579 0453 or 0800 786 529, email info@p3research.co.nz

Hawke's Bay: 06 824 3070 or 0800 141 559, email HBTrials@p3research.co.nz

Wellington: 04 801 0002 or 0800 737 883, email trials@p3research.co.nz

 

Written by Dr Joanna Joseph

Medical Investigator, P3 Research, Wellington Unit

May 2017

 


Are you interested in participating in a study, or want more information?  We're currently looking for participants with mild asthma, COPD, type 2 diabetes, osteoarthritis of the hip or knee and hepatitis C

Further details on these studies can be found on our Current Studies page.  For more information, please contact the staff at your nearest branch. 

Map of clinic sites

Contact Us

Contact us

                                         

Previous Articles:

How Do Clinical Trial Work? - April 2017

  Bookmark this page in your web browserwww.p3research.co.nz - Latest NewsCartNo Items in your Cart